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Abstract
Introduction The steroid receptor RNA activator is a functional
RNA suspected to participate in the mechanisms underlying
breast tumor progression. This RNA is also able to encode for a
protein, Steroid Receptor RNA Activator Protein (SRAP), whose
exact function remains to be determined. Our aim was to assess,
in a large breast cancer cohort, whether levels of this protein
could be associated with outcome or established clinical
parameters.
Methods Following antibody validation, SRAP expression was
assessed by tissue-microarray (TMA) analysis of 372 breast
tumors. Clinical follow-up and parameters such as steroid
receptor and node status were available for all the
corresponding cases. Immunohistochemical scores were
independently determined by three investigators and averaged.
Statistical analyses were performed using standard univariate
and multivariate tests.
Results SRAP levels were significantly (Mann-Whitney rank
sum test, P < 0.05) higher in estrogen receptor-alpha positive
(ER+, n = 271), in progesterone receptor positive (PR+, n =
257) and in older patients (age > 64 years, n = 182). When
considering ER+ tumors, PR+ tumors, or younger patients (≤ 64
years), cases with high SRAP expression had a significantly
(Mantel-Cox test, P  < 0.05) worse breast cancer specific
survival (BCSS) than those with low SRAP levels. SRAP also
appeared as a very powerful indicator of poor prognostic for
BCSS in the subset of ER+, node negative and young breast
cancer patients (Cox regression analysis, n = 60, BCSS Hazard
Ratio = 8.61, P < 0.006).
Conclusions Our data suggest that SRAP levels might provide
additional information on potential risk of recurrence and
negative outcome in a specific set of patients with otherwise
good prognosis when considering only estrogen receptor and
nodal status.
Introduction
Breast cancer remains the second leading cause of cancer-
related deaths in women worldwide and is one of the most fre-
quently diagnosed cancers with an estimated 1,000,000 new
cases detected each year worldwide [1]. Following diagnosis,
several critical prognostic and predictive markers are
assessed in order to determine, for each patient, the most
appropriate treatment to be administered. Estrogen receptor
(ER) status, progesterone receptor (PR) status, nodal status,
tumor size, and grade of malignancy are the classical parame-
ters used to date by clinicians to narrow down prognoses and
weight treatment options [2]. More recently, human epidermal
BCSS: Breast Cancer Specific Survival; DMEM: Dulbecco's modified Eagle's medium; ER: estrogen receptor alpha; FBS: fetal bovine serum; HER: 
human epidermal growth factor receptor; HR: hazard ratio; LBA: ligand binding assay; PBS: phosphate-buffered saline; PR: progesterone receptor; 
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growth receptor (HER)-2, which is over-expressed in about
25% of breast cancers and is associated with a more aggres-
sive disease and a poorer outcome, has also been used as a
prognostic and predictive marker [3]. Recent approaches
such as gene profiling and tissue micro-arrays (TMAs) have
increased our ability not only to identify new potential markers,
but also to rapidly test their potential validity [4,5]. The more
such molecules are identified, the higher become the odds of
finding the optimal combination of markers allowing the deter-
mination of an 'ideal' treatment for any given patient [6].
The steroid receptor RNA activator (SRA) was originally iden-
tified as a functional non-coding RNA increasing the transcrip-
tional activity of ligand-bound steroid receptors [7]. It is
currently believed that this action is mediated by the formation,
at the promoter of target genes, of regulatory complexes con-
taining steroid receptors, SRA, and both positive and negative
protein regulators [8-10]. SRA RNA is over-expressed during
breast, ovarian and uterine tumorigenesis and tumor progres-
sion [11-14]. It has therefore been suggested that by increas-
ing the activity of the ER, SRA could participate in the
mechanisms underlying these events [7,12].
It has now been confirmed that coding SRA transcripts co-
exist in breast cancer cells, with the previously described non-
coding transcripts [15-17]. The corresponding endogenous
protein, steroid receptor RNA activator protein (SRAP), has
been detected by western blot in multiple cell lines as well as
in muscle and breast tissue [15,17-19]. It has been suggested
that, as its RNA counter-part, the protein might also regulate
the activity of estrogen and androgen receptors [10,17-19].
This hypothesis is further corroborated by the identification of
the RNA helicase p68, a well-characterized regulator of ER
activity [20], in nuclear complexes co-immunoprecipitating
with endogenous SRAP [21].
Overall, accumulated data raise the intriguing possibility that
SRAP levels could be associated with ER activity and/or
expression, and could also potentially reflect on the response
of breast cancer patients to endocrine therapy. It has recently
been reported that the relative proportion of coding and non-
coding SRA transcripts varies from one breast tumor to
another and might characterize particular tumor subgroups
[22]. Altogether, this suggests that SRAP expression could
also differ between cases and potentially be a prognostic and/
or predictive indicator in breast cancer. To address this issue,
we have herein investigated the use of TMAs for the expres-
sion of SRAP in 372 cases with a wide range of clinical param-
eters.
Materials and methods
Cell culture
Hela and Michigan Cancer Foundation (MCF)-7 cells (Cedar-
lane Laboratories Ltd., Burlington, ON, Canada) cells were
cultured in DMEM (Gibco, Grand Island, NY, USA) medium
supplemented with 5% FBS (Cansera, Rexdale, ON, Canada),
penicillin (100 units/ml), streptomycin (100 μg/ml) (Gibco,
Grand Island, NY, USA), and 0.3% glucose. Cells were grown
in a 37°C humidified incubator with 5% carbon dioxide. Cells
were transfected with empty vector or plasmids containing
either the full SRA coding sequence and leading to the pro-
duction of a SRAP-V5 tagged protein [16], or a pSuper.retro-
SRA construct expressing a SRA-Interfering RNA (SRA-RNAi)
SRA-Interfering RNA sequence [15], as previously described
[15,16].
Western blot
Total proteins were extracted from cells pellets as previously
outlined [17]. Frozen breast tumor sections were lysed and
sonicated for 30 seconds in ice-cold Sodium-dodecyl-sulfate-
Isolation-Buffer (SIB) containing 60 mM α-glycerophosphate,
1% SDS and a mini-protease inhibitor cocktail tablet (Boe-
hringer Mannheim, Indianapolis, IN, USA) per 10 ml extraction
buffer. Samples were then centrifuged at 13,000 g for 20 min-
utes at 4°C and stored at -20°C until use. Protein concentra-
tion was determined using BCA kit (Pierce Company,
Rockford, IL, USA). Samples containing 75 μg of total protein
were subsequently analyzed by western blot as described pre-
viously [17], using a primary anti-SRAP rabbit polyclonal anti-
body (cat # A300-743A, Bethyl Laboratories, Montgomery,
TX, USA) raised against the C-terminal extremity of SRAP
(peptide 180-237 aa). Signal detection and documentation
was performed using the ChemiDoc imaging system (Bio-Rad,
Mississauga, ON, Canada).
Antibody neutralization experiments
For neutralization experiments, 2 μg of SRAP-180-237 aa
blocking peptide (cat # BP300-743 Bethyl Laboratories,
Montgomery, TX, USA) was pre-incubated with 1 μg of 743A
antibody for two hours at room temperature. A peptide, corre-
sponding to 69 to 89 aa from the Small Breast Epithelial Mucin
[23], was used as a non-specific blocking peptide.
Immunofluorescence
Hela cells cultured on cover-slips were transfected with con-
trol empty vector or plasmid expressing V5-Tagged-SRAP or
SRA-RNAi (see above). Twenty-four hours post-transfection,
coverslips were washed with PBS and cells fixed with 4% for-
maldehyde (Sigma, Oakville, ON, Canada) and 4% sucrose
(Sigma, Oakville, ON, Canada) for 15 minutes at room temper-
ature. Fixed cells were then rinsed with PBS and permeabi-
lized with 0.25% Triton-X100 (Sigma, Oakville, ON, Canada)
in PBS for five minutes. After rinsing with PBS twice, non-spe-
cific binding sites were blocked with 10% BSA (Sigma,
Oakville, ON, Canada) in PBS for 30 minutes at 37°C. Cells
were then incubated overnight at 4°C with 743A Anti-SRAP
antibody diluted at 1/200 in 3% BSA/PBS. After washing with
PBS for 15 minutes, cells were incubated with anti-rabbit sec-
ondary antibody-Cy3 conjugate (Jackson, West Grove, PA,
USA) at a 1/1000 dilution in 3% BSA/PBS for one hour atAvailable online http://breast-cancer-research.com/content/11/5/R67
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room temperature. Cell nuclei were stained with 1 μg/ml
Hoechst (Invitrogen, Burlington, ON, Canada), and coverslips
were mounted onto microscopy slides with FluorSave™Rea-
gent (Calbiochem, La Jolla, CA, USA). Fluorescent images
were captured and visualized with a Nikon Eclipse E1000 epi-
fluorescent microscope at wavelengths of 552 to 620 nm
(CY3), 440 to 450 nm (Hoechst) using ACT-1 software
(Nikon, Mississauga, ON, Canada).
Breast samples and tissue micro-arrays
All invasive breast cancer and normal breast samples used in
the current study were obtained from the Manitoba Breast
Tumor Bank, which operates with the approval of the Faculty
of Medicine, University of Manitoba, Research Ethics Board
[24]. The research reported in this manuscript has been per-
formed with the approval of the Bannatyne Campus, University
of Manitoba, Research Ethics Boards. As described previ-
ously, all tissues accrued to the bank from cases at multiple
centers within Manitoba are frozen at -70°C immediately after
surgical removal. A portion of the frozen tissue from each case
is then processed to create matched formalin-fixed paraffin-
embedded and frozen tissue blocks. The histopathology of all
Manitoba Breast Tumor Bank cases has been previously
assessed and entered into a computerized database to enable
selection based on composition of the tissue as well as clin-
ico-pathological parameters.
Matched frozen and paraffin-embedded sections correspond-
ing to 20 invasive breast tumors and 6 reduction mammoplast-
ies were first selected and evaluated for protein expression by
western blot and immunohistochemistry, respectively. Tumor
ER and PR levels (determined by ligand binding assay (LBA))
ranged from 2.3 to 180 fmol/mg protein and 4.5 to 42 fmol/
mg protein, respectively. The age of patients ranged between
58 and 78 years, and tumor size varied from 15 to 50 mm.
TMAs corresponding to 450 ER positive (LBA > 3 fmol/mg
total protein) and 255 ER negative (LBA ≤ 3 fmol/mg total pro-
tein) cases were constructed from primary invasive breast car-
cinomas, as described before [25,26]. Duplicate core tissue
samples (0.6 mm diameter) were taken from selected areas of
maximum cellularity for each tumor. Two controls, correspond-
ing to cases positive and negative for SRAP expression,
respectively, were included in each TMA run to check for run
to run reproducibility. From our studies, cases with lost follow-
up, unknown grade or nodal status, or data on SRAP expres-
sion (loss of a core during processing) were removed. All char-
acteristics were ultimately available for 372 breast cases.
Tumors corresponded to 271 cases associated with ER-posi-
tive status (ER > 3 fmol/mg total protein, as assessed by LBA)
that were treated by surgery and then tamoxifen endocrine
therapy with or without radiation therapy. Remaining tumors
corresponded to 99 cases associated with ER-negative status
(ER ≤ 3 fmol/mg total protein, as assessed by LBA) that were
treated by surgery with or without radiation therapy, tamoxifen
endocrine therapy or chemotherapy. The whole cohort has ER
levels ranging 0 to 331 fmol/mg protein (median 23 fmol/mg
protein) and spanned a wide range of PR levels 0 to 1591
fmol/mg protein (median 17.95 fmol/mg protein). Nottingham
grade [27] was also known for all 372 tumors, which were
assigned to low (n = 79, scores 3 to 5), moderate (n = 205,
scores 6 to 7) or high (n = 88, scores 8 to 9) categories. Age
of patients ranged from 25 to 92 years old (median 64 years).
The clinical follow-up ranged from 1 to 179 months (median
85 months). Out of 372 cases, 172 had a recurrence of the
disease and 141 died from the disease.
Breast tumor tissue sections and TMAs were stained with an
anti-SRAP antibody (cat # A300-743A, Bethyl Laboratories,
Montgomery, TX, USA) using an automated tissue immunos-
tainer (Discovery Staining Module, Ventana Medical Systems,
Tucson, AZ, USA) at a dilution of 1:250, as described previ-
ously [25,26]. Slides were viewed and scored using standard
light microscopy.
Quantification and SRAP staining cut-off selection
SRAP protein expression was assessed using a previously
described semi-quantitative scoring consisting of an assess-
ment of both staining intensity (scale 0 to 3) and the percent-
age of positive cells (0 to 100%), which, when multiplied,
generate an H-score ranging from 0 to 300 [25,26]. TMA
slides were independently scored by three investigators
(GPS, CCP and YY). Average of values scored by the three
investigators were calculated. There is no relevant clinical cut-
off point reported for SRAP. The median H-score value of
76.67 was arbitrarily set as cut-point. Breast cancers were
therefore considered high SRAP expressors when their aver-
age score exceeded 76.67 and low SRAP expressors when
their H-score was lower than or equal to 76.67. Cohen kappa
coefficient for the semi-quantitative H scores were 0.43, 0.50
and 0.65, indicating a moderate to substantial inter-rater
agreement between the three readers [28].
Statistical analysis
Differences between SRAP expression in different subgroups
(such as ER positive versus ER negative or node positive ver-
sus node negative, for example) were tested using the Mann-
Whitney rank sum test, two sided. Box and whiskers represen-
tation was performed with boxes at 25 to 75% and whiskers
at 10 to 90%. Potential distributions of low and high SRAP
cases in other clinical-pathological variables were tested using
contingency methods (Fisher's exact test). Survival analyses
were performed using the Mantel-Cox log-rank test to gener-
ate Kaplan-Meier curves. Breast Cancer Specific Survival
(BCSS) was defined as the time from initial surgery to the date
of death attributable to breast cancer only. Recurrence-free
survival (RFS) was defined as the time from initial surgery to
the date of clinically documented local or distant disease
recurrence or death attributed to breast cancer. Deaths
caused by other known diseases were censored. StatisticalBreast Cancer Research    Vol 11 No 5    Yan et al.
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analyses were carried out using GraphPad Prism 5 (Graph-
Pad, San Diego, CA, USA) and PASW Statistics 17 (SPSS
Inc. Chicago, IL, USA).
Cox proportional hazards model was used to test the statisti-
cal independence and significance of the different predictors
on BCSS (events modeled: deaths attributable to breast can-
cer only) and RFS (events modeled consisting of recurrences
or deaths attributed to breast cancer). The predictors consid-
ered in the model were: age at diagnosis (age ≤ median age
64, age > median age 64); ER-alpha status (ER ≤ 3 consid-
ered negative, ER > 3 are positive); node status (positive, neg-
ative); SRAP (low SRAP ≤ 76.67, high SRAP > 76.67); all
two, three and four-way interactions involving SRAP.
Results
Anti-SRAP antibody validation
The ability of the 743A anti-SRAP antibody (Bethyl, Mont-
gomery, TX, USA) to specifically recognize SRAP was first
assessed by western blot analysis of total protein extracted
from MCF-7 breast cancer cells, previously shown to express
this protein [15-17]. A doublet, migrating at the expected
apparent size of about 30 kDa, is specifically detected (Figure
1, left panel). As anticipated, the signal is decreased when the
antibody is pre-incubated with an excess of corresponding
blocking (743A + BP) but not unrelated (743A + Unr-P) pep-
tide. The specificity of the signal recognized by 743A anti-
SRAP antibody is further demonstrated by its decrease when
cells are expressing SRA RNAi or by the appearance of an
additional band in cells expressing a V5-Tagged-SRAP con-
struct (Figure 1, right panel).
To further validate the use of 743A anti-SRAP antibody for in
situ analyses, similar experiments were performed by immun-
ofluorescence in Hela cells. As shown Figure 2, SRAP signal
is detected in the nucleus and the cytoplasm of Hela cells
(743A panels). As expected, this signal is decreased when the
primary antibody is pre-incubated with the blocking peptide
(743A + BP panels) or when cells expressed SRA RNAi
(SRA-RNAi panel). Inversely, cells expressing exogenous V5-
tagged-SRAP showed an increased signal detected with the
743A antibody (SRAP-V5 panels).
Differential SRAP expression in breast tissues
SRAP expression was subsequently assessed by western blot
in a small series of 20 breast tumors and 6 normal breast sam-
ples as detailed in the Materials and Methods section. A sig-
nal, which varied in intensity between tumor samples and
corresponding to SRAP of 30 kDa was detected in most
cases (Figure 3, red arrow). Overall, this signal appears
stronger in tumors than in normal tissues. It should however be
emphasized that SRAP of 30 kDa is not detectable in all
tumors (see Tumors 3 and 4) nor normal tissues (see Normal
1). Interestingly, two additional bands migrating at apparent
sizes of 40 kDa (see Tumors 1, 9, 10) and 25 kDa (see Tumors
1, 2, 10) are also detected in some tumor cases but not in nor-
mal tissues. All these bands are specifically recognized by
743A anti-SRAP antibody, as shown by extinction of the sig-
nals in neutralization experiments (Figure 3, middle panel). It
should also be noted, that in MCF-7 but not in Hela cells, over-
exposure of the blot led to the detection of the 40 kDa band.
Immunohistochemical analysis performed on matched paraffin
sections confirms that SRAP is detectable in epithelial cells
within normal ducts (Figure 4a). A wide range of staining can
be observed in breast cancers with some tumors showing a
weak (Figures 4b, c) and others an intense staining (Figure
4d). The specificity of the staining is demonstrated by its
decrease when the primary antibody is pre-incubated with the
corresponding blocking peptide (Figures 4e, f) but not with a
non-specific/irrelevant peptide (data not shown).
Figure 1
Western blot detection of about 30 kDa SRAP in MCF-7 cells Western blot detection of 30 kDa SRAP in MCF-7 cells. Total proteins, extracted from MCF-7 breast cancer cells, were analyzed by western blot 
using 743A polyclonal anti-steroid receptor RNA activator protein (SRAP) antibody as described in the Materials and Methods section (743A). The 
antibody has been pre-incubated with its corresponding blocking peptide (743A + BP) or with an unrelated peptide (743A + Unr-P). In a parallel 
series of experiments, cells were transfected with an empty vector (Unt), SRA-RNAi or a construct encoding V5-tagged SRAP (SRAP-V5) as indi-
cated in the Materials and Methods section. MCF = Michigan Cancer Foundation.Available online http://breast-cancer-research.com/content/11/5/R67
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Tissue micro-array analysis of SRAP expression in 372 
breast cancer cases
We have investigated SRAP expression in TMAs correspond-
ing to a large cohort of breast cancer cases with different
established clinical parameters. Staining and scoring were
performed as described in the Materials and Methods section.
Examples of staining and corresponding H-scores are shown
in Figure 5. SRAP staining varies greatly from one sample to
another, with H-scores ranging from 0 to 196.67 (n = 372,
median = 76.67, average = 81.27). SRAP expression, ER/PR/
node status, Nottingham grade [27], size of the tumor, patient
age at surgery and clinical follow-up were available for 372
patients.
As illustrated in Figure 6a, significant (Mann-Whitney rank sum
test, two-sided, P < 0.0001) H-score values are higher in ER-
positive than in ER-negative tumors (ER positive, n = 271,
median = 81.67 versus ER negative, n = 101, median =
58.33). Similarly, SRAP staining is significantly stronger in PR-
positive than in PR-negative cases (PR positive, n = 256,
median = 80 versus PR negative, n = 116, median = 66.67).
Tumors with higher Nottingham grade had a significantly lower
SRAP staining than both low and medium grade lesions (high
grade, n = 88, median = 60 versus low grade, n = 79, median
= 85 and medium grade, n = 205, median = 79.17). When
cases were divided into two groups using the median age at
surgery (median H-score 64), older patients had a significantly
higher SRAP expression detected in their tumors than younger
patients (older patients, n = 183, median = 80.83 versus
younger patients, n = 189, median = 73.83). No difference in
SRAP staining was observed between node-positive and
node-negative tumors or between small and bigger lesions.
To further investigate potential non-random distributions of
SRAP H-score staining in different tumor subgroups, we have
arbitrarily divided the cohort into low and high SRAP
Figure 2
Detection of SRAP in Hela cells by fluorescent immunocytochemistry Detection of SRAP in Hela cells by fluorescent immunocytochemistry. Steroid receptor RNA activator protein (SRAP) was detected in untransfected 
(743A), steroid receptor RNA activator Interfering RNA transfected (SRA-RNAi) and SRAP-V5 infected Hela cells using 743A anti-SRAP antibody 
as described in Materials and Methods. 743A + BP = 743A antibody was pre-incubated in an excess of neutralizing peptide. Bar = 20 μm.Breast Cancer Research    Vol 11 No 5    Yan et al.
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expressors by selecting the median H-score value as cut-off
point (low SRAP, H-score lower or equal to 76.67, n = 190;
high SRAP, H-scores higher than 76.67, n = 182; Figure 6b).
Contingency table analyses showed that low SRAP cases
were significantly (Fisher's exact test) over-represented in ER-
negative, PR-negative and higher grade tumors compared
with ER-positive, PR-positive and lower grade tumors, respec-
tively (Table 1). Similarly, a higher proportion of low SRAP
expressors was found in lesions from younger patients. Identi-
cal proportions of low and high SRAP expressors were found
in node-positive and node-negative tumors, and in small and
large lesions.
Low SRAP expression is associated with longer survival 
among ER-positive, PR-positive and younger breast 
cancer patients
When analyzing the cohort as a whole and most of the case
subgroups detailed in Table 1, no difference was found in
BCSS between high and low SRAP expressors (data not
shown). Interestingly patients whose tumors were ER positive
had a significantly longer BCSS and RFS (Figures 7a, b) when
their primary tumor expressed lower levels of SRAP (Mantel-
Cox, P = 0.0065 and P = 0.0212, respectively). When con-
sidering PR-positive cases, patients whose primary tumors
expressed low SRAP also had a better BCSS and RFS (Fig-
ures 7a, b; Mantel-Cox, P = 0.0052 and P = 0.0041, respec-
tively). In younger patients (age ≤ 64 years old, corresponding
to values lower and equal to median age at surgery) Low
SRAP levels were similarly associated with a longer BCSS
and RFS (Figures 7a, b; Mantel-Cox, P = 0.0117 and P =
0.002, respectively). No significant differences between low
SRAP and high SRAP were found in the whole cohort or any
other subgroups defined in Table 1.
Lower SRAP level is a significant predictor of survival in 
younger patients whose tumors are ER positive and 
node negative
In multivariate regression analyses of the whole cohort, age,
ER status and nodal status were, as expected, associated with
poor prognosis (Table 2). SRAP, however, did not act as a
proportional predictor in either BCSS or RFS analysis. In the
ER-negative group, neither SRAP nor any interaction was a
predictor of survival. In the ER-positive group (n = 271), High
SRAP was associated with a higher rate of death due to breast
cancer (hazard ratio (HR) = 4.213, P = 0.007) and higher rate
of recurrence (HR = 3.392, P = 0.005). In this subgroup, inter-
action between SRAP and age approached and reached sig-
nificance, when considering BCSS and RFS, respectively (P
= 0.060 and P = 0.030). Looked at in isolation, the interaction
becomes clear (Figure 8). Within the ER-positive subgroup,
SRAP is as a poor prognostic marker for BCSS and RFS in
the subset of node-negative and young breast cancer patients
(n = 60, HR = 8.616, P = 0.006 and HR = 3.566, P = 0.011,
respectively), but not in older or node positive patients (Fig-
ures 8a, b).
To further establish the different prognostic value of high
SRAP levels in different age subgroups, patients with ER-pos-
itive/node-negative tumors (n = 130) have been grouped
according to their age (corresponding to quartiles: 0 to 25%,
26 to 50%, 51 to 75%, 76 to 100%). Patients whose age fell
in the first and second quartiles (24 to 55 and 56 to 64 years
old), but not older patients, had a significant decrease in sur-
vival when their primary tumors expressed high SRAP levels
(Figure 8c).
Figure 3
Western blot detection of 30 kDa, 25 kDA and 40 kDa SRAP in breast tumor tissues Western blot detection of 30 kDa, 25 kDA and 40 kDa SRAP in breast tumor tissues. Protein extracts from MCF-7 cells, Hela cells, breast tumors (1 
to 9, red numbers) and normal (1 to 6 blue numbers) breast tissues were examined by western blot and visualized with 743A anti-steroid receptor 
RNA activator protein (SRAP) antibody (upper panel) as described in the Materials and Methods. The same extracts were analyzed with 743A anti-
SRAP antibody pre-absorbed with an excess of blocking peptide (middle panel) or with an antibody targeting β-actin (lower panel). MCF = Michigan 
Cancer Foundation.Available online http://breast-cancer-research.com/content/11/5/R67
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Figure 4
SRAP immunohistochemical detection in breast tissue sections SRAP immunohistochemical detection in breast tissue sections. Steroid receptor RNA activator protein (SRAP) expression was assessed in (a) nor-
mal and (b to f) tumor paraffin-embedded tissue sections using 743A anti-SRAP antibody as described in the Materials and Methods section. (f) A 
serial section adjacent to section E has been treated with 743A pre-incubated with specific blocking peptide. Bar = 50 μm.Breast Cancer Research    Vol 11 No 5    Yan et al.
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Figure 5
Tissue micro-array analysis of SRAP expression Tissue micro-array analysis of SRAP expression. Immunohistochemical detection of steroid receptor RNA activator protein (SRAP) was performed 
using 743A polyclonal anti-SRAP antibody on tissue micro-arrays corresponding to a large cohort of breast tumors. For each case, SRAP staining 
has been assessed and an H-score determined as detailed in the Material and Methods section. Examples of three cores with different H-scores are 
provided. Bar = 100 μm.Available online http://breast-cancer-research.com/content/11/5/R67
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Discussion
In the present study, we have established that several SRAP-
like peptides were detectable in breast tumor tissues. Interest-
ingly, in ER positive, and more predominantly within node neg-
ative and younger patients, higher levels of the corresponding
signal were associated with poor survival.
No data reporting specific detection of SRAP employing the
antibody used in our experiments (cat # A300-743A) has
been published. It was therefore critical to first validate the use
of this antibody for western blot and immunohistochemistry
analyses. A doublet migrating at the apparent size of about 30
kDa is detected by western blot in MCF-7 as well as in multiple
other cell lines (Figure 1 and data not shown). This size corre-
sponds to the size previously observed using different SRAP
antibodies [15,17,19]. The signal decreases upon peptide
neutralization and during SRA RNAi experiments. An addi-
tional band, also recognized by anti-V5 antibody (data not
shown), appears when cells are transfected with a construct
encoding an exogenous V5-tagged SRAP. Altogether, these
observations strongly suggest that 743A antibody specifically
recognizes SRAP.
The endogenous SRAP signal is detected mainly in the cyto-
plasm of cancer cells in vitro. In some cases, a speckled stain-
ing can also be seen in the nucleus. This is in agreement with
both localizations previously observed for exogenous tagged
SRAP [16]. This also corroborates data from Jung and col-
leagues [21], who co-immunoprecipitated endogenous SRAP
from both nuclear and cytoplasmic protein extracts from Hela
cells [10,21].
Figure 6
Distribution of SRAP H-scores in 372 breast cancer cases Distribution of SRAP H-scores in 372 breast cancer cases. (a) Box and whiskers representation showing the distribution of steroid receptor RNA 
activator protein (SRAP) H-scores in the whole cohort (Total) and in different subgroups. For each group the median is depicted by the thick horizon-
tal bar, the box delineates 25th to 75th percentiles and the whiskers 10 to 90 percentiles (b) Frequency distribution of SRAP H-scores in the whole 
cohort (Total). Median H-score of 76.67 delineates Low SRAP and a High SRAP subgroups.Breast Cancer Research    Vol 11 No 5    Yan et al.
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Western blot analysis of breast tumors revealed the presence
in some tumors of two additional bands migrating at an appar-
ent size of about 25 kDa and about 40 kDa. Both signals dis-
appear when the antibody is pre-incubated with the
corresponding blocking peptide. This suggests that as well as
30 kDa SRAP, these proteins are also specifically recognized
by 743A antibody. We have already reported the detection,
within some breast tumors, of both 30 kDa and 25 kDa migrat-
ing bands [15]. The antibody used was, in contrast to 743A,
targeting the N-terminal extremity of SRAP, because it was
raised against SRAP amino acids 20 to 34. No bands migrat-
ing at the apparent size of 40 kDa had been previously
observed. It should however be noted that when blots are
overexposed, the 40 kDa band is detectable in MCF-7 cells
but not in Hela cells (Figure 3), suggesting potential cell/tissue
specificity in the mechanisms responsible for the generation of
the corresponding peptide. This raises the possibility that this
particular 'higher mass' or 'larger' peptide might be missing
SRAP N-terminal extremity but contain additional unknown
sequences. The identity of all these SRAP-like peptides
remains to be determined. It should however be stressed that
several SRA splice variants have now been characterized
[10,13,17]. Proteins potentially encoded by some of these
alternatively spliced transcripts are missing SRAP N-terminal
extremity but still contain SRAP amino acids 180 to 236 rec-
ognized by 743A antibody. For example, Ensembl transcript
[Ensembl: ENSESTT00000035630] containing intron-1, is
expected to encode for a peptide [Ensembl:
ENSESTP00000035630] corresponding to the last 162
amino acids of SRAP and with a predicted molecular mass of
18 kDa. As well, other alternative splicing events, such as
intron-1 retention conjugated with exon-3 deletion [17], pre-
dicts a 220 amino acid residue protein (molecular weight
24.68 kDa) identical to SRAP in its N- and C-terminal extremity
but differing in the central sequence.
Further studies are urgently needed to establish the nature of
the different splicing events potentially involved in the genera-
tion of the different SRA transcripts and their potential protein
products. This is critical if we consider that SRA was originally
described as a functional RNA whose activity depended on
the integrity of the core sequence determined by exon-2 to
exon-5 [29]. It has recently been shown that the balance
between fully spliced SRA and transcripts still containing
intron-1 varied between breast tumors and characterized par-
ticular tumor subgroups [30]. Interestingly, alteration of this
balance led to a change in breast cancer cell growth [30].
Taken together with size differences between SRA transcripts
detectable by Northern blot in breast cancer cells and cells
from other origins [7], this suggests that alternative splicing
events, leading to different SRA RNAs and potentially to differ-
ent SRAP-like proteins, might participate in the development
of different breast cancer cell phenotypes.
Alternative post-translational modifications might also be
responsible for the apparent differences in SRAP molecular
mass. For example, a lysine residue at position 21 of the SRAP
human sequence is conserved in all vertebrates and is pre-
dicted to be sumoylated (data not shown). Sumoylation of this
residue could potentially participate to the shift in migration
from 30 kDa to 40 kDa [31,32]. Further studies are warranted
to address this possibility.
Although only six normal breast cases were analyzed, they all
expressed only 30 kDa SRAP at a level lower than that seen in
most tumors. This is in agreement with the previous observa-
tion that SRA RNA is overall expressed at lower levels in nor-
mal compared with matched adjacent tumor tissue [14]. This
also raises the possibility that mechanisms responsible for the
generation of the 25 kDa and 40 kDa SRAP-like peptides are
less frequent in normal than in tumor cells.
Using 743A antibody, significant higher levels of SRAP are
found in ER-positive tumors, in PR-positive tumors, and in
lower grade tumors. This fits with the pattern of expression of
a known activator of steroid receptor, the steroid receptor co-
activator 1 (SRC1). Indeed, high SRC1 protein levels have
recently been shown to positively correlate with ER, PR levels
and low grade in a large cohort of 426 breast cancer patients
[33]. In their study, Green and colleagues reported that
patients whose tumors expressed higher SRC1 levels had an
Table 1
Distribution of low and high SRAP cases in case subgroups
Case subgroups Low SRAP High SRAP Total P value
n (%) n (%)
ER - 72 (71) 29 (29) 101 < 0.0001
ER+ 115 (42) 156 (58) 271
PR - 78 (67) 37 (33) 115 0.0053
PR+ 112(44) 145 (56) 257
Node - 95 (55) 80 (45) 172 0.2545
Node + 95 (48) 102 (52) 200
Low (3-5) 30 (39) 47 (61) 77 < 0.0001
Med (6-7) 97 (47) 109 (53) 206
High (8-9) 63 (71) 26 (29) 89
Low size (≤ 2.5 cm) 105 (54) 90 (46) 195 0.2992
High size (> 2.5 cm) 85 (48) 92 (52) 177
Age ≤ 64 113 (60) 77 (40) 190 0.0013
Age > 64 77 (42) 105 (58) 182
Total 190 182 372
P-values correspond to Fisher's exact test. ER = estrogen receptor; 
PR = progesterone receptor; SRAP = steroid receptor RNA 
activator protein; + = positive; - = negative.Available online http://breast-cancer-research.com/content/11/5/R67
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Figure 7
Low SRAP is an indicator of better survival for younger patients and patients with ER positive or PR positive tumors Low SRAP is an indicator of better survival for younger patients and patients with ER positive or PR positive tumors. Kaplan-Meier breast cancer-
specific (a) death survival and (b) recurrence-free survival plots are shown for patients with ER+ tumors (n = 271), PR+ tumors (n = 256), and for 
patients younger than 65 years old (n = 189). P values correspond to Mantel-Cox log-rank test. ER = estrogen receptor; PR = progesterone recep-
tor; SRAP = steroid receptor RNA activator protein; + = positive; - = negative.Breast Cancer Research    Vol 11 No 5    Yan et al.
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Figure 8
SRAP as a poor prognostic indicator in younger patients whose tumors are ER positive and node negative SRAP as a poor prognostic indicator in younger patients whose tumors are ER positive and node negative. Cox multivariate analyses have been per-
formed as described in the Materials and Methods section. The events modeled were (a) death attributable to breast cancer, or (b) recurrence or 
death attributed to breast cancer. Hazard ratios within different estrogen receptor positive (ER+) subgroups are shown as squares and 95% confi-
dence intervals as error bars. (c) Kaplan-Meier breast cancer specific death survival (BCSS) plots are shown for patients with ER+/node negative 
tumors (n = 130). Panels correspond to the four different age quartiles: 0 to 25%, age 25 to 55 years old patients; 26 to 50%, age 56 to 64 years 
old patients; 51 to 75%, age 65 to 71 years olds; 76 to 100%, age 72 to 82 years old patients. P values correspond to Mantel-Cox log-rank test. 
SRAP = steroid receptor RNA activator protein.Available online http://breast-cancer-research.com/content/11/5/R67
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overall longer survival and a lower recurrence rate [33]. In con-
trast, we found that high SRAP expression is a strong indicator
of poor survival in ER-positive patients. It should be noted that
a similar finding was obtained when using a training set, vali-
dation set method and X-tile software [34] (data not shown).
All 271 women whose tumors were ER positive had been
treated with tamoxifen following surgery. Further analyses are
needed to establish whether SRAP should be considered as
a prognostic factor, a predictive factor, or both.
Interestingly, the potential indicator power of SRAP appears
limited to younger patients whose tumors are ER positive and
node negative. It should be stressed that the age cut-point of
64 years (corresponding to median age at time of surgery) has
been chosen to divide the cohorts in subgroups with compa-
rable number of cases. A cut-point of 51 years, average age
for spontaneous menopause [35,36], would have been more
informative to establish the potential link between menopausal
status and SRAP prognostic value. The number of cases
younger than 51 was, however, too low to perform meaningful
statistical analyses. For example, only 21 out of the 271 ER-
positive patients were younger than 51 years. Menopause age
follows a Gaussian distribution ranging roughly from 40 to 60
years [35,36]. As patients' menopausal status is not regis-
tered in the Manitoba Breast Tumor Database, women
younger than 51 years could also potentially be menopaused.
It is therefore not possible to extrapolate whether SRAP prog-
nostic value is directly linked to menopausal status. Further
studies, performed on a cohort consisting of comparable num-
bers of known pre- and post-menopausal women should be
initiated to clarify this issue.
The particular group of younger patients identified in this
cohort (i.e ER positive, node negative) usually benefits from
better prognosis and is considered as having an increased
likelihood of responding to tamoxifen therapy. Our data, how-
ever, suggest that among this group, women with higher levels
of SRAP might need additional treatment compared with
women with lower SRAP levels.
We have previously reported that the detection in breast tumor
extracts of 30 kDa SRAP by western blot, but not 25 kDa
SRAP, might correspond to a better outcome for ER-positive/
node-negative patients [17]. There is therefore an apparent
disagreement with the present TMA results that show that
higher SRAP is an indicator of shorter survival in ER-positive/
node-negative patients. This apparent divergence could be
due a variety of reasons. It may potentially result from differ-
ences in the cohorts studied. Our previous cohort was indeed
smaller (n = 74 versus n = 130), the median ER levels was
higher (45.5 fmol/mg versus 37 fmol/mg), the number of
Table 2
Cox multivariate analysis of breast cancer specific and recurrence-free survivals
Breast cancer specific survival Recurrence-free survival
Cases Predictor Haz Rat 95% CI P Haz Rat 95% CI P
SRAP 1.580 0.35-7.01 0.547 0.356 0.29-5.63 0.729
Whole cohort Age 2.576 1.50-4.40 < 0.001 1.507 1.39-3.60 < 0.0001
n = 372 ER 0.213 0.12-0.36 < 0.001 0.124 0.24-0.64 < 0.0001
Node 3.214 1.8-5.61 < 0.001 1.84 1.67-4.39 < 0.0001
SRAP 1.489 0.31-6.99 0.614 1.387 0.29-6.43 0.676
ER- Age 2.556 1.30-5.00 0.006 2.515 1.29-4.88 0.007
n = 101 Node 2.788 1.33-5.82 0.006 2.547 1.25-5.18 0.010
SRAP × age 0.216 0.01-2.61 0.228 0.231 0.01-2.79 0.249
SRAP × node 1.421 0.31-6.99 0.688 1.422 0.29-6.43 0.686
SRAP 4.213 1.47-12.0 0.007 3.392 1.46-7.87 0.005
ER+ Age 1.637 0.75-3.54 0.210 1.656 0.88-3.09 0.113
n = 271 Node 3.466 1.45-8.26 0.005 2.721 1.40-5.27 0.003
SRAP × age 0.316 0.09-1.05 0.060 0.337 0.12-0.89 0.030
SRAP × node 0.474 1.47-12.0 0.216 0.539 1.46-7.87 0.210
CI = confidence interval; ER = estrogen receptor; Haz Rat = hazard ratio; SRAP = steroid receptor RNA activator protein; + = positive; - = 
negative.
P values correspond to cox regression model. Significant P values are bolded.Breast Cancer Research    Vol 11 No 5    Yan et al.
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events was different (n = 7 deaths versus n = 26) and patients'
ages were not available. Further, in the previous western blot
analysis, which was performed as outlined earlier with an anti-
body recognizing the N-termina l  r e g i o n  o f  S R A P ,  3 0  k D a
SRAP was detected in only 24 of 74 cases [17]. Using 743A,
we have in the present study detected SRAP signal in all but
2 out of 130 ER-positive/node-negative patients. It should also
be stressed that, as mentioned above, SRAP staining
assessed in the present TMAs corresponds to multiple SRAP-
like peptides (25 kDa, 30 kDa and 40 kDa SRAP) whereas
only the 30 kDa SRAP was considered in the first study. This
also raises the possibility that different peptides might have
different prognostic or predictive values.
Conclusions
Altogether, we have found that several SRAP-like peptides are
expressed in breast tumors and that their detection by immu-
nohistochemistry could be used as a new prognostic/predic-
tive marker in younger patients with ER-positive/node-negative
breast cancer. Additional studies, performed with other anti-
bodies are warranted to confirm this observation and further
establish whether specific SRAP-like peptides have additional
predictor values.
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